Fujii Takayuki, Hagihara Masao, Mitamura Keiko, Nakashima Shiori, Ohara Shin, Uchida Tomoyuki, Inoue Morihiro, Okuda Moe, Yasuhara Atsuhiro, Murakami Jurika, Duong Calvin, Iwatsuki-Horimoto Kiyoko, Yamayoshi Seiya, Kawaoka Yoshihiro
Department of Hematology, Eiju General Hospital, Japan.
Division of Hematology, Department of Medicine, Keio University School of Medicine, Japan.
Intern Med. 2022 Jun 1;61(11):1681-1686. doi: 10.2169/internalmedicine.9209-21. Epub 2022 Mar 26.
Objective Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread globally. Although the relationship between anti-SARS-CoV-2 immunoglobulin G (IgG) antibodies and COVID-19 severity has been reported, information is lacking regarding the seropositivity of patients with particular types of diseases, including hematological diseases. Methods In this single-center, retrospective study, we compared SARS-CoV-2 IgG positivity between patients with hematological diseases and those with non-hematological diseases. Results In total, 77 adult COVID-19 patients were enrolled. Of these, 30 had hematological disorders, and 47 had non-hematological disorders. The IgG antibody against the receptor-binding domain of the spike protein was detected less frequently in patients with hematological diseases (60.0%) than in those with non-hematological diseases (91.5%; p=0.029). Rituximab use was significantly associated with seronegativity (p=0.010). Conclusion Patients with hematological diseases are less likely to develop anti-SARS-CoV-2 antibodies than those with non-hematological diseases, which may explain the poor outcomes of COVID-19 patients in this high-risk group.
目的 由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的冠状病毒病（COVID-19）已在全球范围内传播。尽管已有关于抗SARS-CoV-2免疫球蛋白G（IgG）抗体与COVID-19严重程度之间关系的报道，但对于包括血液系统疾病在内的特定类型疾病患者的血清阳性情况仍缺乏相关信息。方法 在这项单中心回顾性研究中，我们比较了血液系统疾病患者和非血液系统疾病患者的SARS-CoV-2 IgG阳性情况。结果 总共纳入了77例成年COVID-19患者。其中，30例患有血液系统疾病，47例患有非血液系统疾病。血液系统疾病患者中针对刺突蛋白受体结合域的IgG抗体检测频率（60.0%）低于非血液系统疾病患者（91.5%；p=0.029）。使用利妥昔单抗与血清阴性显著相关（p=0.010）。结论 与非血液系统疾病患者相比，血液系统疾病患者产生抗SARS-CoV-2抗体的可能性较小，这可能解释了该高危组中COVID-19患者的不良预后。
